Callyope vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Callyope (Paris, AWS Pioneers 2026) raised .41M seed with 8 clinical trials ongoing, using speech AI to detect psychiatric deterioration early and deliver objective data between visits.
About
Callyope is a Paris-based clinical AI company founded to improve outcomes in mental health through passive, continuous monitoring. The company applies speech analysis and machine learning to detect early signals of psychiatric deterioration, enabling clinicians to intervene before crises occur. Its core technology processes vocal biomarkers to track mood, cognition, and behavioral patterns over time without requiring patients to self-report symptoms.\n\nCallyope's platform is designed for integration within clinical workflows, targeting psychiatrists, mental health hospitals, and digital health providers. The product supports remote patient monitoring between visits, generating objective data streams that augment clinician judgment. Unlike consumer wellness apps, Callyope operates within regulated clinical environments and is built to meet the evidentiary standards required for reimbursement and adoption in European and US health systems.\n\nThe company raised a $2.41 million seed round to fund product development and clinical validation. It currently has eight clinical trials ongoing and was selected for the AWS Healthcare Accelerator Pioneers 2026 cohort, reflecting recognition of its technical and scientific rigor. Callyope's pipeline of trial data positions it to pursue regulatory clearance and reimbursement pathways, which would unlock hospital procurement and enterprise mental health contracts at scale.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.